New research shows amyloid buildup is a downstream effect—not the cause of cognitive decline. The real Root Causes or drives are inflammation, insulin resistance, toxins, and nutrient loss.
For decades, the world’s top Alzheimer’s researchers have chased a single culprit: beta-amyloid, the sticky protein that clumps into plaques in the brain. This theory—the amyloid hypothesis—has shaped nearly every major drug trial, absorbed billions of research dollars, and guided public understanding of the disease.
But there’s a problem: despite all the attention, drugs that target amyloid have repeatedly failed to restore memory or stop decline. Even the newest “successful” drugs, like Lecanemab, offer only a modest slowing of progression—and only in the earliest stages. Meanwhile, people with perfectly healthy brains have been found to harbor large amounts of amyloid plaque.
These facts force us to confront a new reality: amyloid is not the root cause of Alzheimer’s—it’s a downstream effect of deeper metabolic, inflammatory, and immune imbalances.
The Cracks in the Amyloid Hypothesis
The amyloid hypothesis took hold in the 1980s, when scientists first identified amyloid plaques in the brains of people who had died with Alzheimer’s. For years, researchers assumed that these plaques were toxic clumps that directly caused neurons to die. It seemed logical—find the plaque, remove it, fix the disease.
That logic has failed the test of time. Over 30 years and hundreds of clinical trials later, not one amyloid-targeting drug has reversed Alzheimer’s or restored normal cognition.
Recent investigations have also exposed cracks in the foundation of the amyloid model itself. In 2024, Nature formally retracted a highly cited 2006 paper that claimed to show a specific amyloid fragment (called Aβ*56) caused memory loss in mice. Image data had been manipulated to produce the desired result. That fraudulent study helped solidify the amyloid-centric view and guided funding priorities for nearly two decades.
As Science and STAT News have reported, the fallout has prompted soul-searching in the field. If one of the cornerstone studies was flawed—and if eliminating amyloid doesn’t restore memory—then perhaps we’ve been looking at the wrong end of the problem.
What the Evidence Really Shows
Modern research paints a far more complex picture of Alzheimer’s disease. Beta-amyloid accumulation is real, but it is a response to damage, not the root cause.
- Metabolic dysfunction comes first.
Brain imaging studies show that glucose metabolism begins to falter years before amyloid appears. This “type 3 diabetes” pattern—driven by insulin resistance, mitochondrial stress, and impaired energy production—creates the perfect storm for brain injury and cell death. When neurons can’t make enough energy, they misfold proteins, produce excess free radicals, and lose the ability to clear debris. Amyloid builds up as a consequence. - Chronic inflammation drives the damage.
The brain’s immune cells, called microglia, become overactive in response to infection, toxins, trauma or systemic inflammation. Over time, this state of “neuroinflammation” leads to oxidative stress, impaired blood flow, and leaky barriers that allow more toxins in. Amyloid is now believed to rise as a protective mechanism—a way for the brain to trap pathogens or neutralize free radicals. In this view, amyloid isn’t the villain; it’s the firefighter that shows up to a blaze started elsewhere. - Tau and synaptic dysfunction are more predictive.
Another protein, tau, forms tangles inside neurons and correlates far more closely with cognitive decline than amyloid levels do. Tau changes often begin earlier, suggesting that cellular stress, not plaque buildup, starts the domino effect. - Amyloid appears in healthy brains too.
Autopsy and PET imaging studies reveal that up to 30% of cognitively normal older adults have significant amyloid deposits yet remain sharp and symptom-free. Conversely, some people with dementia symptoms have little or no amyloid at all. This mismatch underscores that amyloid alone does not determine who gets Alzheimer’s.
Why Amyloid-Targeted Drugs Keep Failing
If amyloid were the cause, clearing it should dramatically improve cognition. It doesn’t. Drugs like Lecanemab can reduce plaque volume on brain scans, yet their clinical effects are small. Providing only a few months’ delay in symptom progression over 18 months of treatment. Side effects like brain swelling and brain bleeding are common.
The lesson? Removing the smoke doesn’t put out the fire. You can remove plaques from the brain, but if the underlying inflammation, insulin resistance, or toxic exposure continues, the degenerative process marches on.
A 2025 review in Nature Reviews Neurology summed it up clearly: “Amyloid reduction can modify downstream injury, but it does not correct the upstream metabolic and inflammatory drivers of disease.” In other words, amyloid is part of the pathology, but not the cause.
A Systems-Biology View of Alzheimer’s
When we step back and view the brain as part of a larger biological network, a different story emerges. Alzheimer’s is not a single disease—it’s the final common pathway of multiple system failures:
- Insulin resistance reduces glucose uptake in the brain, starving neurons of energy.
- Mitochondrial dysfunction produces oxidative stress and impairs repair mechanisms.
- Chronic inflammation from infections, poor diet, or gut dysbiosis accelerates cell damage.
- Toxin exposure and nutrient deficiencies disrupt signaling and detoxification.
- Vascular decline impairs blood flow and neuroprotection.
- Hormonal and trophic factor decline – decreases in BDNF (Brain Derived Neurotrophic Factor), estrogen, testosterone, DHEA, VEGF and others leads to poor neuronal survival, metabolism, and decreased neurogenesis, synaptic plasticity and mitochondrial function.
Amyloid is what happens after these upstream processes have gone unchecked. It’s the end effect of a body and a brain under siege.
A Shift in Focus: From Plaque to Process
If amyloid is an outcome, not a cause, then the path forward is clear: we must focus on restoring balance in the systems that sustain the brain. That means addressing the root causes that create the biochemical environment for amyloid to appear in the first place.
Functional Medicine and precision prevention models, like the Bredesen ReCODE 2.0 Protocol, take this multi-factorial approach. They address insulin resistance, inflammation, infection, toxins, nutrient gaps, and lifestyle stressors—all of which drive the metabolic collapse that precedes amyloid accumulation.
Working with a practitioner to identify and correct these imbalances often leads to stabilization or even reversal of the disease. Something no amyloid drug has achieved.
The Takeaway
Amyloid is not the cause of Alzheimer’s—it’s the evidence of the brain trying to protect itself from deeper dysfunction.
A more hopeful future lies not in another round of failed plaque-clearing drugs, but in understanding and correcting the underlying metabolic, inflammatory, and immune imbalances that give rise to the disease.
When we focus on the root systems, not just the end effects, the brain has a remarkable ability to heal itself.
Dr. Coby L. Hanes, DC, IFMCP is an Institute for Functional Medicine–certified physician with over 30 years of experience in Functional and Integrative Medicine. He is among the first doctors in Oregon certified in ReCODE 2.0 (Reversal of Cognitive Decline), the groundbreaking protocol developed by Dr. Dale Bredesen to prevent and reverse Alzheimer’s disease and cognitive decline.
Dr. Hanes specializes in autoimmune disease, metabolic disorders, brain health, and gut health, helping patients uncover and address the root causes of chronic illness through personalized, evidence-informed care. He has completed extensive postgraduate education including Mastering the Thyroid and Mastering Brain Chemistry, and is currently pursuing advanced training in Functional Neurology. Dr. Hanes also holds certification in Herbal and Botanical Medicine from the University of Colorado School of Pharmacy.
Through his expertise in Functional Medicine and ReCODE 2.0, Dr. Hanes works with patients facing Alzheimer’s disease, autoimmune disorders, and other complex chronic illnesses—helping them rebuild health, clarity, and vitality from the inside out.
You can reach him at:
Website: Center4FunctionalMedicine.com
email: DocHanes@Center4Wellness.com
Key References (2024–2025):
- Nature Reviews Neurology (2025): “Beyond Amyloid: Revising the Mechanisms of Alzheimer’s Pathogenesis.”
- Science (2024): “Faked Beta-Amyloid Data: What Does It Mean?”
- STAT News (2025): “Retractions Shake the Foundations of the Amyloid Hypothesis.”
- NIH Alzheimer’s Research Database (2024): “Multifactorial Mechanisms Underlying Neurodegeneration.”
- NEJM (2023): “Lecanemab in Early Alzheimer’s Disease.”
